Cambridge Cognition (LSE:COG) marked World Alzheimer's Day by joining a three-way Partnership intended to make dementia diagnosis in the UK faster and more accurate. The company is small, recently recapitalised and still loss-making. The question is how its cognitive testing technology fits into the new diagnostic pathway, and what the arrangement could mean for a Business that earns most of its Revenue from clinical trials.

Digital cognitive assessment

Cambridge Cognition develops "digital cognitive assessments" used in clinical studies, Drug Development and patient care. Its main platforms are CANTAB, a set of computerised cognitive tests, and Winterlight, which analyses speech to assess cognition. Pharmaceutical companies use its tools to measure cognitive effects in trials, while the company is also pursuing healthcare applications. In addition, it announced the launch of a brain health study with Oura on 28 May 2026. Rob Baker is the chief executive, and the shares are quoted on AIM under the ticker COG.

The C2N and Alzheimer's Trust partnership

On 21 September 2026, Cambridge Cognition announced a partnership with C2N Diagnostics and The Alzheimer's Trust to create an integrated pathway for earlier and more accurate detection of Alzheimer's disease in the UK. Under the arrangement, C2N supplies its PrecivityAD2 blood test, which measures amyloid and tau biomarkers, while Cambridge Cognition provides CANTAB Pathway, a touchscreen platform with three escalating tiers of cognitive assessment. The Alzheimer's Trust contributes national phlebotomy, MRI and patient support infrastructure, and healthcare professionals order through the Trust.

The announcement cited diagnostic accuracy of 90% for the combined approach, compared with 70% for standard GP care. Rob Baker said the UK's "dementia diagnostic challenge" demands "bold, collaborative action". C2N's chief executive said the partnership "could be a model in other parts of the world", while The Alzheimer's Trust described the approach as patient-centric. No financial terms or volumes were disclosed, so the revenue contribution cannot yet be assessed. Separately, chair Nick Rodgers bought 19,000 shares at 27.4p on 18 September 2026, lifting his holding to 98,892 shares.

Interim results and balance sheet

On 16 September 2026, the company reported revenue of £5.0 million for the six months to 30 June, up 16%, with gross Margin rising three percentage points to 75%. The adjusted EBITDA loss narrowed to £0.3 million from £0.4 million, and the loss before tax was £0.7 million. New sales orders fell 13% to £6.0 million, although the company noted a £1.0 million deal signed after the period. The order book stood at £16.1 million, which management said gives visibility over more than £10.0 million of 2026 revenue.

Cash was only £0.6 million at 30 June. After the period, the company completed a £2.6 million fundraising at 35p per share and repaid its £0.9 million Debt Facility in full, leaving it debt-free. It plans to use the proceeds partly for CE marking and FDA clearance, paediatric datasets and automated speech recognition for Winterlight. Management expects "significant revenue growth" in 2026, although £0.7 million of contracted revenue has been rescheduled into 2027.

Risks and uncertainties

Clinical trial revenue can be delayed when sponsors reschedule studies, as the 2027 shift shows. Healthcare adoption of cognitive testing depends on regulatory clearances and NHS or private uptake, and the partnership's Economics are undisclosed. The company's cash cushion is modest even after the raise, so it needs to convert its order book efficiently. The share purchase by the chair at 27.4p sits below the 35p fundraising price.

Conclusion

Cambridge Cognition is supplying the cognitive assessment layer of a new UK Alzheimer's diagnostic pathway alongside blood testing from C2N and infrastructure from The Alzheimer's Trust. The partnership extends CANTAB into healthcare, but with no financial terms disclosed, its near-term financial impact remains uncertain beside a recovering trials business.